CellSeed Inc. (JP:7776)
:7776
Want to see JP:7776 full AI Analyst Report?
7776 Stock Chart & Stats
¥259.00
-¥7.00(-1.73%)
At close: 4:00 PM EST
¥259.00
-¥7.00(-1.73%)
Day’s Range― - ―
52-Week Range¥231.00 - ¥597.00
Previous CloseN/A
Volume900.50K
Average Volume (3M)621.90K
Market Cap
¥10.45B
Enterprise Value¥7.80B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.31
Shares Outstanding38,987,920
10 Day Avg. Volume981,780
30 Day Avg. Volume621,903
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageReported debt-to-equity near 0.07–0.15 indicates low financial leverage, giving the company structural flexibility to raise capital or absorb shocks without heavy interest burdens. This conservatism supports longer runway for R&D and commercialization in capital-intensive biotech.
Healthy Gross MarginsConsistently high gross margins (48%–69%) reflect strong underlying unit economics in cell-sheet products and services. Durable product-level profitability means that if revenue scales or SG&A is controlled, operating margins can improve materially, supporting sustainable long-term profitability.
Niche Regenerative ExpertiseSpecialization in cell-sheet engineering and regenerative medicine creates a technical moat and differentiated IP/know-how. This focused business model targets high-value clinical and manufacturing niches where barriers to entry and long development cycles favor incumbents with proven expertise.
Bears Say
Persistent Cash BurnOperating and free cash flow have been negative each year, worsening in 2025, indicating the business lacks self-funded operations. Persistent cash burn increases reliance on external financing, heightening dilution and execution risk for multi-year clinical and commercialization programs.
Severe Revenue DeteriorationA 56.7% YoY revenue decline in 2025 and prior volatility undermine the firm's ability to scale fixed-cost intensive operations. Declining top-line reduces operating leverage potential, stresses margins, and weakens the case for sustainable commercial traction in coming quarters.
Very Large Operating LossesExtremely negative net margin (~−1,319%) and persistently negative returns on equity reflect a cost base far exceeding current revenue. Such deep losses risk ongoing equity erosion, increased dilution if financed, and challenge management's ability to demonstrate a path to positive profitability.
CellSeed Inc. News
7776 FAQ
What was CellSeed Inc.’s price range in the past 12 months?
CellSeed Inc. lowest stock price was ¥231.00 and its highest was ¥597.00 in the past 12 months.
What is CellSeed Inc.’s market cap?
CellSeed Inc.’s market cap is ¥10.45B.
When is CellSeed Inc.’s upcoming earnings report date?
CellSeed Inc.’s upcoming earnings report date is May 13, 2026 which is in 2 days.
How were CellSeed Inc.’s earnings last quarter?
CellSeed Inc. released its earnings results on Feb 13, 2026. The company reported -¥7.31 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.31.
Is CellSeed Inc. overvalued?
According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued.
Does CellSeed Inc. pay dividends?
CellSeed Inc. does not currently pay dividends.
What is CellSeed Inc.’s EPS estimate?
CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSeed Inc. have?
CellSeed Inc. has 38,987,920 shares outstanding.
What happened to CellSeed Inc.’s price movement after its last earnings report?
CellSeed Inc. reported an EPS of -¥7.31 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.305%.
Which hedge fund is a major shareholder of CellSeed Inc.?
Currently, no hedge funds are holding shares in JP:7776
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSeed Inc.
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―